Latest News and Press Releases
Want to stay updated on the latest news?
-
SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
No Significant CA4P Drug Safety Issues IdentifiedInitial Efficacy in Favor of CA4P, with 22% of CA4P Patients Responding versus 9% in the Control ArmEnrollment in the Study Continuing SOUTH SAN...
-
SOUTH SAN FRANCISCO, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
One patient of four (25%) achieved a complete remissionNo dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif., March 15, 2017 (GLOBE...
-
SOUTH SAN FRANCISCO, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
-
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completionThree additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1,...
-
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...